Beta Drugs (NSE:BETA) Interest Expense: ₹-84 Mil (TTM As of Mar. 2026)


NSE:BETA Beta Drugs Ltd NSE:BETA
91 GF Score
Price ₹2,366.80
GF Value ₹1,975.60
Valuation Modestly Overvalued
! 6 Warning Signs
View Full Analysis

What is Beta Drugs Interest Expense?

Beta Drugs NSE:BETA +8.06% 91 Interest Expense is ₹-84 Mil as of Mar. 2026. GuruFocus rates NSE:BETA with a GF Score™ of 91/100 and a GF Value™ of ₹1,975.60 (Modestly Overvalued). The stock has 6 warning signs investors should review.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Beta Drugs's interest expense for the three months ended in Mar. 2026 was ₹ -39 Mil. Its interest expense for the trailing twelve months (TTM) ended in Mar. 2026 was ₹-84 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Beta Drugs's Operating Income for the three months ended in Mar. 2026 was ₹ 129 Mil. Beta Drugs's Interest Expense for the three months ended in Mar. 2026 was ₹ -39 Mil. Beta Drugs's Interest Coverage for the quarter that ended in Mar. 2026 was 3.27. The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Beta Drugs  (NSE:BETA) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Beta Drugs's Interest Expense for the three months ended in Mar. 2026 was ₹-39 Mil. Its Operating Income for the three months ended in Mar. 2026 was ₹129 Mil. And its Long-Term Debt & Capital Lease Obligation for the three months ended in Mar. 2026 was ₹1,333 Mil.

Beta Drugs's Interest Coverage for the quarter that ended in Mar. 2026 is calculated as

Interest Coverage=-1* Operating Income (Q: Mar. 2026 )/Interest Expense (Q: Mar. 2026 )
=-1*128.813/-39.442
=3.27

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Beta Drugs Interest Expense Historical Data

* Premium members only.

The historical data trend for Beta Drugs's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Beta Drugs Interest Expense Chart

Beta Drugs Annual Data
Trend Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25 Mar26
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only -17.89 -22.80 -26.78 -69.89 -153.11

Beta Drugs Quarterly Data
Mar17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24 Dec24 Mar25 Sep25 Dec25 Mar26
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -18.77 -32.85 0.00 -44.34 -39.44
NSE:BETA
91GF Score
Beta Drugs Ltd NSE:BETA
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Beta Drugs Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹-84 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of ₹-84 Mil mean?
Beta Drugs (NSE:BETA) has a Interest Expense of ₹-84 Mil as of Mar. 2026. Interest Expense is the amount a company pays on its long-term debt. View historical data on Beta Drugs and its competitors.
Is Beta Drugs' Interest Expense too high?
Beta Drugs' current Interest Expense is ₹-84 Mil. Overall, Beta Drugs has a GF Score™ of 91/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Beta Drugs' Interest Expense compare to ZTS and UTHR?
Beta Drugs' Interest Expense of ₹-84 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Drug Manufacturers company?
A good Interest Expense depends on the Drug Manufacturers industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Beta Drugs and its competitors. Beta Drugs's current Interest Expense is ₹-84 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beta Drugs stock overvalued right now?
Based on GuruFocus' analysis, Beta Drugs (NSE:BETA) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹1,975.60, compared to a current price of ₹2,366.80 — trading 19.8% above its estimated fair value. The current Interest Expense is ₹-84 Mil. Beta Drugs' overall GF Score™ is 91/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Beta Drugs (NSE:BETA), the current Interest Expense is ₹-84 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Beta Drugs (NSE:BETA) Overvalued in 2026?

Based on GuruFocus' analysis, Beta Drugs stock appears to be overvalued. The current stock price of ₹2,366.80 is trading 19.8% above its estimated GF Value™ of ₹1,975.60. GuruFocus considers Beta Drugs to be Modestly Overvalued.

Key valuation signals for NSE:BETA:

  • Interest Expense: ₹-84 Mil
  • GF Value™: ₹1,975.60 vs. price of ₹2,366.80 (19.8% above fair value)
  • GF Score™: 91/100 with 6 warning signs

No single metric tells the full story. See the NSE:BETA stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Beta Drugs Business Description

Address SCO-184, First Floor, Sector-5, Panchkula, HR, IND, 134114
Beta Drugs Ltd operates in the pharmaceutical industry. The company manufactures and sells Oncology products in the form of tablets, capsules, oral formulations, and injections. It sells the products in India and also exports them to other countries, of which key revenue is derived from the sales made in India.
91GF Score

Get the complete analysis for NSE:BETA

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

₹2,366.80
Price
₹1,975.60
GF Value